vs
Side-by-side financial comparison of CytoMed Therapeutics Ltd (GDTC) and Largo Inc. (LGO). Click either name above to swap in a different company.
CytoMed Therapeutics Ltd is the larger business by last-quarter revenue ($115.4K vs $87.6K, roughly 1.3× Largo Inc.).
CytoMed Therapeutics Ltd is a clinical-stage biopharmaceutical company focused on developing innovative allogeneic chimeric antigen receptor (CAR-T) cell therapies for treating hematological malignancies and solid tumors. It primarily serves global oncology patient populations and advances candidates targeting unmet medical needs in the immuno-oncology segment.
Largo Inc. is a Canada-based critical minerals producer focused on sustainable vanadium extraction and processing. It operates core production assets in Brazil, supplying high-purity vanadium products for steel manufacturing, grid-scale energy storage, and industrial clients across global markets.
GDTC vs LGO — Head-to-Head
Income Statement — Q2 FY2025 vs Q3 FY2025
| Metric | | |
|---|---|---|
| Revenue | $115.4K | $87.6K |
| Net Profit | — | $-52.0K |
| Gross Margin | — | — |
| Operating Margin | — | — |
| Net Margin | — | -59.3% |
| Revenue YoY | — | — |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q3 25 | — | $87.6K | ||
| Q2 25 | $115.4K | $54.4K | ||
| Q1 25 | — | $28.2K | ||
| Q3 24 | — | $100.7K | ||
| Q2 24 | — | $70.7K | ||
| Q1 24 | — | $42.2K |
| Q3 25 | — | $-52.0K | ||
| Q2 25 | — | $-40.0K | ||
| Q1 25 | — | $-18.3K | ||
| Q3 24 | — | $-18.7K | ||
| Q2 24 | — | $-3.9K | ||
| Q1 24 | — | $715 |
| Q3 25 | — | -59.3% | ||
| Q2 25 | — | -73.6% | ||
| Q1 25 | — | -64.9% | ||
| Q3 24 | — | -18.6% | ||
| Q2 24 | — | -5.6% | ||
| Q1 24 | — | 1.7% |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-855.3K | — |
| Free Cash FlowOCF − Capex | $-855.4K | — |
| FCF MarginFCF / Revenue | -741.5% | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q3 25 | — | — | ||
| Q2 25 | $-855.3K | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $5.0K |
| Q3 25 | — | — | ||
| Q2 25 | $-855.4K | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | -741.5% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 6.93× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
